European Journal of Nutrition

, 48:349 | Cite as

Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels

  • Rolf JordeEmail author
  • Yngve Figenschau
Original Contribution



Studies have suggested that vitamin D may be important for both insulin sensitivity and insulin secretion, and that supplementation with vitamin D may subsequently prevent development of type 2 diabetes.

Aim of the study

The objective of the current study was to test the hypothesis that supplementation with vitamin D would improve glycaemic control in subjects with type 2 diabetes.


Thirty-six subjects with type 2 diabetes, treated with metformin and bed-time insulin, were randomised to supplementation with cholecalciferol (40,000 IU per week) versus placebo for 6 months. Thirty-two subjects participated throughout the entirety of the study. Fasting blood samples were drawn before and at the end of the 6 month study without the previous bed-time insulin injection. The insulin and metformin doses were not changed throughout the study.


After 6 months, the fasting glucose, insulin, C-peptide, fructosamine, and HbA1c levels were not significantly different from baseline values. In addition, changes in these parameters (values at 6 months minus values at baseline) did not differ between the vitamin D and the placebo group.


We were not able to demonstrate that vitamin D supplementation had a significant effect on glucose metabolism in subjects with type 2 diabetes but without vitamin D deficiency. Further studies are needed in larger groups of subjects with type 2 diabetes or impaired glucose tolerance, who also exhibit low serum 25-hydroxyvitamin D levels.


Diabetes mellitus Glucose Placebo-controlled study Vitamin D 



The present study was supported by a grant from the Norwegian Diabetes Association. The superb assistance by Annika Gustafsson and the other nurses at the Clinical Research Unit and by Inger Myrnes and Astrid Lindvall at the Department of Medical Biochemistry, University Hospital of North Norway, is gratefully acknowledged.


  1. 1.
    Baynes KC, Boucher BJ, Feskens EJ, Kromhout D (1997) Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 40:344–347CrossRefGoogle Scholar
  2. 2.
    Beaulieu C, Kestekian R, Havrankova J, Gascon-Barré M (1993) Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes 42:35–43CrossRefGoogle Scholar
  3. 3.
    Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28Google Scholar
  4. 4.
    Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M (2004) Expression of 25-hydroxyvitamin D3–1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 89–90:121–125CrossRefGoogle Scholar
  5. 5.
    Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ (1995) Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38:1239–1245CrossRefGoogle Scholar
  6. 6.
    Cade C, Norman AW (1986) Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 119:84–90CrossRefGoogle Scholar
  7. 7.
    Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820–825Google Scholar
  8. 8.
    Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ (2008) Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes 57:2619–2625CrossRefGoogle Scholar
  9. 9.
    Iqbal A, Jorde R, Figenschau Y (2006) Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study. J Int Med 260:53–61CrossRefGoogle Scholar
  10. 10.
    Jorde R, Svartberg J, Sundsfjord J (2005) Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 23:1639–1644CrossRefGoogle Scholar
  11. 11.
    Jorde R, Hagen T (2006) Screening for diabetes using HbA1c in elderly subjects. Acta Diabetol 43:52–56CrossRefGoogle Scholar
  12. 12.
    Kamycheva E, Jorde R, Figenschau Y, Haug E (2007) Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest 30:126–132Google Scholar
  13. 13.
    Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R (2008) Serum 1, 25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 47:87–91CrossRefGoogle Scholar
  14. 14.
    Leahy JL (2005) Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36:197–209CrossRefGoogle Scholar
  15. 15.
    Lind L, Pollare T, Hvarfner A, Lithell H, Sørensen OH, Ljunghall S (1989) Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 11:141–147Google Scholar
  16. 16.
    Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM (2005) Dietary calcium, vitamin D and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 28:2926–2932CrossRefGoogle Scholar
  17. 17.
    Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sørensen OH, Wide L (1987) Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance-a prospective randomized double-blind study. Acta Med Scand 222:361–367Google Scholar
  18. 18.
    Maestro B, Campión J, Dávila N, Calle C (2000) Stimulation by 1, 25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47:383–391CrossRefGoogle Scholar
  19. 19.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefGoogle Scholar
  20. 20.
    Need AG, O’Loughlin PD, Horowitz M, Nordin BE (2005) Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol 62:738–741CrossRefGoogle Scholar
  21. 21.
    Norman AW, Frankel JB, Heldt AM, Grodsky GM (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823–825CrossRefGoogle Scholar
  22. 22.
    Ojuka EO (2004) Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 63:275–278CrossRefGoogle Scholar
  23. 23.
    Orwoll E, Riddle M, Prince M (1994) Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 59:1083–1087Google Scholar
  24. 24.
    Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB (2006) Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29:650–656CrossRefGoogle Scholar
  25. 25.
    Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92:2017–2029CrossRefGoogle Scholar
  26. 26.
    Pittas AG, Harris SS, Stark PC, Dawson-Hughes B (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30:980–986CrossRefGoogle Scholar
  27. 27.
    Scragg R (2008) Vitamin D and type 2 diabetes: are we ready for a prevention trial? Diabetes 57:2565–2566CrossRefGoogle Scholar
  28. 28.
    Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89:552–572CrossRefGoogle Scholar
  29. 29.
    Zittermann A (2006) Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 92:39–48CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Institute of Clinical MedicineUniversity of TromsøTromsøNorway
  2. 2.Medical ClinicUniversity Hospital of North NorwayTromsøNorway
  3. 3.Department of Medical BiochemistryUniversity Hospital of North NorwayTromsøNorway
  4. 4.Institute of Medical BiologyUniversity of TromsøTromsøNorway

Personalised recommendations